Arnaud Mary completed his PhD in neurosciences in 2022 at the Université Côte-d’Azur in Nice, France, working at the Institute of Molecular and Cellular Pharmacology (IPMC) in Prof. Frédéric Checler’s team under the supervision of Dr. Mounia Chami. His research centred on the toxic effects of APP C-terminal fragments and the involvement of AMP-activated protein kinase (AMPK) signalling in mitochondrial dysfunctions, amyloid and Tau pathologies, and neuroinflammation in Alzheimer’s disease (AD). Since October 2022, he has been working as a postdoctoral researcher in the Neuroinflammation group at the LCSB. Here, his primary research aim is to study the mechanisms of pyroptosis, the pro-inflammatory cell death of microglia, and its importance in AD. Arnaud works with various models (cell lines, primary microglia, induced pluripotent stem cell-derived microglia, AD mouse models, and human fluids), and is perfecting his mastery of a variety of techniques (immunofluorescence, flow cytometry, live and in vivo microscopy, biomarker analysis).